Cover Image
Market Research Report

Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas - Forecast to 2022

Published by MarketsandMarkets Product code 572660
Published Content info 170 Pages
Delivery time: 1-2 business days
Price
Back to Top
Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas - Forecast to 2022
Published: October 27, 2017 Content info: 170 Pages
Description

"The drug discovery services market projected to grow at a CAGR of 11.6%."

The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022. The major factors driving the growth of this market are increasing research and development expenditure, inclination of major pharmaceutical companies towards outsourcing to avoid hurdles, and increasing demand for outsourcing of analytical testing and clinical trial services. However, the high cost involved in drug discovery and development, stringent regulations governing drug discovery, and animal usage are restraining the growth of this market

"The hit-to-lead generation segment is expected to register the highest CAGR during the forecast period."

On the basis of process, the market is classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by attributed to the emerging advanced technologies for high-throughput screening (HTS).

"The medicinal chemistry segment to grow at the fastest rate during the forecast period."

By type, the drug discovery services market is segmented into medicinal chemistry, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry segment is expected to register the highest growth rate during the forecast period. Increasing R&D expenditure, growing number of drug discovery and developmental activities, and increasing inclination of pharmaceutical companies towards outsourcing are among the major factors driving the growth of the medicinal chemistry segment.

"North America to hold the largest share and Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

Geographically, the drug discovery services market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the drug discovery services market. The large share of this segment can be attributed to the presence of leading CROs and pharmaceutical companies in this region. The Asia Pacific region is estimated to grow at the fastest rate which can be attributed to less stringent regulations and economical manufacturing costs.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1 - 40%; Tier 2 - 30% and Tier 3 - 30%
  • By Designation - C-level - 62%, Director Level - 21%, Others - 17%
  • By Region - North America - 50%, Europe - 20%, Asia Pacific - 20% , RoW- 10%

Key players operating in the drug discovery services market include Thermo Fisher Scientific (US), Albany Molecular Research Inc. (AMRI) (US), Charles River Laboratories (US), Evotec (Germany), Domainex (UK), GenScript (US), Covance (US), Selcia (UK), Viva Biotech (China), WuXi AppTec (China), SRI International (US), Pharmaceutical Product Development, LLC (PPD) (US), GVK Biosciences (India), Jubilant Biosys (India), GE Healthcare (US), Merck (Germany), Lonza (Switzerland), Piramal Enterprises (India), Advinus Therapeutics (India), Promega Corporation (US), Syngene International (India), Aurigene (India), Agilent Technologies (US), Ubiquigent (UK), and ChemBridge Corporation (US).

Research Coverage:

The report analyses the drug discovery services market by process, type, drug type, therapeutic area, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.

Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.

The report provides insights on the following strategies:

  • Market Penetration: The report analyzes the drug discovery services market by process, type, drug type, and therapeutic area
  • Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the drug discovery services market
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various drug discovery services across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the drug discovery services market
Table of Contents
Product Code: PH 5682

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
  • 2.2. SECONDARY DATA
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
  • 2.3. PRIMARY DATA
    • 2.3.1. KEY DATA FROM PRIMARY SOURCES
  • 2.4. MARKET SIZE ESTIMATION
    • 2.4.1. BOTTOM-UP APPROACH
    • 2.4.2. TOP-DOWN APPROACH
  • 2.5. DATA TRIANGULATION
  • 2.6. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. DRUG DISCOVERY SERVICES MARKET OVERVIEW
  • 4.2. EUROPEAN DRUG DISCOVERY SERVICES MARKET SHARE, BY THERAPEUTIC AREA AND COUNTRY
  • 4.3. DRUG DISCOVERY SERVICES MARKET, BY TYPE
  • 4.4. GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing R&D expenditure
      • 5.2.1.2. Increasing demand for outsourcing analytical testing and clinical trial services
      • 5.2.1.3. Initiatives for research on rare diseases
      • 5.2.1.4. Focus on drug discovery
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of drug discovery and development
      • 5.2.2.2. Stringent regulations governing drug discovery, and animal usage
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Introduction of advanced technologies
      • 5.2.3.2. Patent expiries to boost the demand for drug discovery
    • 5.2.4. BURNING ISSUES
      • 5.2.4.1. Need for harmonization of regulations, IP rights

6. DRUG DISCOVERY SERVICES MARKET, BY PROCESS

  • 6.1. INTRODUCTION
  • 6.2. TARGET SELECTION
  • 6.3. TARGET VALIDATION
  • 6.4. HIT-TO-LEAD IDENTIFICATION
  • 6.5. LEAD OPTIMIZATION
  • 6.6. CANDIDATE VALIDATION

7. DRUG DISCOVERY SERVICES MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. MEDICINAL CHEMISTRY
  • 7.3. BIOLOGY SERVICES
  • 7.4. DRUG METABOLISM AND PHARMACOKINETICS (DMPK)

8. DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

  • 8.1. INTRODUCTION
  • 8.2. SMALL MOLECULES
  • 8.3. BIOLOGICS

9. DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

  • 9.1. INTRODUCTION
  • 9.2. ONCOLOGY
  • 9.3. NEUROLOGY
  • 9.4. CARDIOVASCULAR DISEASES
  • 9.5. RESPIRATORY DISEASES
  • 9.6. DIABETES
  • 9.7. OTHER THERAPEUTIC AREAS

10. DRUG DISCOVERY SERVICES MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. UK
    • 10.3.3. FRANCE
    • 10.3.4. REST OF EUROPE (ROE)
  • 10.4. ASIA PACIFIC (APAC)
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA PACIFIC (ROAPAC)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET SHARE ANALYSIS

12. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 12.1. THERMO FISHER SCIENTIFIC
  • 12.2. MERCK
  • 12.3. GE HEALTHCARE
  • 12.4. ALBANY MOLECULAR RESEARCH, INC. (AMRI)
  • 12.5. CHARLES RIVER LABORATORIES INTERNATIONAL
  • 12.6. EVOTEC
  • 12.7. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC. (PPD)
  • 12.8. JUBILANT BIOSYS
  • 12.9. COVANCE
  • 12.10. GENSCRIPT BIOTECH CORPORATION
  • 12.11. AURIGENE DISCOVERY TECHNOLOGIES
  • 12.12. WUXI APPTEC
  • 12.13. SYNGENE

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INDUSTRY INSIGHTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: TOTAL GLOBAL PHARMACEUTICAL R&D SPENDING, 2012 TO 2022 (USD BILLION)
  • TABLE 2: R&D SPENDING, PHRMA MEMBER-COMPANIES (USD BILLION)
  • TABLE 3: ACTIVITIES OUTSOURCED IN THE PHARMACEUTICAL INDUSTRY (2014 VS. 2015)
  • TABLE 4: RESEARCH PROJECTS FUNDED BY IRDIRC BODIES
  • TABLE 5: AVERAGE COST OF DRUGS APPROVED BY YEAR
  • TABLE 6: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 7: TARGET SELECTION MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8: TARGET VALIDATION MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 9: HIT-TO-LEAD IDENTIFICATION PROCESS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: LEAD OPTIMIZATION MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 11: CANDIDATE VALIDATION MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 13: MEDICINAL CHEMISTRY SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: BIOLOGY SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 17: SMALL MOLECULES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18: BIOLOGICS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS, 2016
  • TABLE 20: GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 21: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 22: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 25: DRUG DISCOVERY SERVICES MARKET FOR DIABETES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 28: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 29: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 30: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 31: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 32: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 33: US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 34: US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 35: US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 36: US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 37: CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 38: CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 39: CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 40: CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 41: EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2012 & 2014
  • TABLE 42: EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY/REGION, 2015 -2022 (USD MILLION)
  • TABLE 43: EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 44: EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 45: EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 46: EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 47: PHARMACEUTICAL R&D INVESTMENTS IN GERMANY (2010-2014)
  • TABLE 48: GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 49: GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 50: GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 51: GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 52: UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 53: UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 54: UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 55: UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 56: FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 57: FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 59: FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 60: PHARMACEUTICAL R&D INVESTMENTS IN ITALY, 2009-2014
  • TABLE 61: PHARMACEUTICAL R&D EXPENDITURE IN BELGIUM, 2010-2014
  • TABLE 62: PHARMACEUTICAL PRODUCTION AND R&D EXPENDITURE IN DENMARK, 2012-2014
  • TABLE 63: ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 64: ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 65: ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 66: ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 67: TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2016
  • TABLE 68: APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 69: APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 70: APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 71: APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 72: APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 73: CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 74: CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 75: CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 76: CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 77: JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 78: JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 79: JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 80: JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 81: INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 82: INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 83: INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 84: INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 85: ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 86: ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 87: ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 88: ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)
  • TABLE 89: ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015-2022 (USD MILLION)
  • TABLE 90: ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 91: ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015-2022 (USD MILLION)
  • TABLE 92: ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL DRUG DISCOVERY SERVICES MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2017 VS. 2022 (USD BILLION)
  • FIGURE 6: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2017 VS. 2022 (USD BILLION)
  • FIGURE 7: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2017 VS. 2022 (USD BILLION)
  • FIGURE 8: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2017 VS. 2022 (USD BILLION)
  • FIGURE 9: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2017 VS. 2022 (USD BILLION)
  • FIGURE 10: INCREASING DEMAND FOR OUTSOURCING OF ANALYTICAL TESTING AND CLINICAL TRIAL SERVICES TO DRIVE MARKET GROWTH
  • FIGURE 11: ONCOLOGY SEGMENT TO COMMAND THE LARGEST MARKET SHARE OF EUROPEAN DRUG DISCOVERY SERVICES MARKET IN 2017
  • FIGURE 12: MEDICINAL CHEMISTRY TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD (2017-2022)
  • FIGURE 13: ASIA PACIFIC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022
  • FIGURE 14: DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 15: NUMBER OF REGISTERED STUDIES (2000-2017)
  • FIGURE 16: HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE IN 2017
  • FIGURE 17: MEDICINAL CHEMISTRY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE DRUG DISCOVERY SERVICES MARKET
  • FIGURE 18: SMALL MOLECULES-THE LARGEST SEGMENT IN THE DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPES
  • FIGURE 19: ONCOLOGY SEGMENT TO HOLD THE LARGEST SHARE IN DRUG DISCOVERY SERVICES MARKET IN 2017
  • FIGURE 20: TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY (2016)
  • FIGURE 21: GEOGRAPHIC SNAPSHOT (2016): APAC MARKETS ARE EMERGING AS NEW GROWTH HOTSPOTS
  • FIGURE 22: NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 23: PHARMACEUTICAL R&D EXPENDITURE IN THE US (1990-2014)
  • FIGURE 24: TOTAL CANADIAN PHARMACEUTICAL TRADE (2004-2016) (USD BILLION)
  • FIGURE 25: YEARLY EMPLOYMENT IN MANUFACTURING PORTION OF PHARMACEUTICAL SECTOR (2005-2016)
  • FIGURE 26: PHARMACEUTICAL R&D EXPENDITURE IN EUROPE (2010-2014)
  • FIGURE 27: EUROPE: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 28: APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 29: DRUG DISCOVERY SERVICES MARKET: MARKET SHARE (2016)
  • FIGURE 30: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)
  • FIGURE 31: MERCK: COMPANY SNAPSHOT (2016)
  • FIGURE 32: GE HEALTHCARE: COMPANY SNAPSHOT (2016)
  • FIGURE 33: ALBANY MOLECULAR RESEARCH, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 34: CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2016)
  • FIGURE 35: EVOTEC: COMPANY SNAPSHOT (2016)
  • FIGURE 36: JUBILANT BIOSYS: COMPANY SNAPSHOT (2016)
  • FIGURE 37: LABCORP: COMPANY SNAPSHOT (2016)
  • FIGURE 38: GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 39: SYNGENE: COMPANY SNAPSHOT (2016)
Back to Top